The phosphatidylinositol-3-kinase (PI3K)/Akt and the mammalian target of rapamycin
(mTOR) signaling pathways are two pathways crucial to many aspects of cell growth and …

Neuron-specific enolase (NSE) is known to be a cell specific isoenzyme of the glycolytic
enzyme enolase. In vertebrate organisms three isozymes of enolase, expressed by different …

Neuroendocrine neoplasms (NENs) arise from the diffuse neuroendocrine cell system and
may occur at many different disease sites. Most frequently, these neoplasms occur in the …

Background Everolimus, an oral inhibitor of mammalian target of rapamycin (mTOR), has
shown antitumor activity in patients with advanced pancreatic neuroendocrine tumors, in two …

Background The multitargeted tyrosine kinase inhibitor sunitinib has shown activity against
pancreatic neuroendocrine tumors in preclinical models and phase 1 and 2 trials. Methods …

Background Everolimus, an oral inhibitor of the mammalian target of rapamycin (mTOR), has
shown antitumour activity in patients with advanced pancreatic neuroendocrine tumours. We …

Peptide receptor radionuclide therapy (PRRNT) is a molecularly targeted radiation therapy
involving the systemic administration of a radiolabelled peptide designed to target with high …

Multiple endocrine neoplasia type 1 (MEN1), a rare tumor syndrome that is inherited in an
autosomal dominant pattern, is continuing to raise great interest for endocrinology …

Therapeutic approaches for management of metastatic disease include surgical, medical,
radiological and nuclear medicine strategies. More recently, novel molecular targeted drugs …

The NCCN Guidelines for Neuroendocrine and Adrenal Tumors provide recommendations
for the management of adult patients with neuroendocrine tumors (NETs), adrenal gland …